The management team will be joined by two new members in Helena Jansson, Chief Business Officer and Deputy CEO, and Vaidrius Navikas, Chief Medical Officer. At the same time, Christina Erixon will step down from the management team. Following these changes, the management team will consist of Anna Ljung, Annica Magnusson, Helena Jansson, Mark Beveridge and Vaidrius Navikas.

“First of all, I would like to thank Christina for her excellent efforts for Moberg Pharma and for her valuable participation in the management team. At the same time, I am very pleased to welcome Helena and Vaidrius to Moberg Pharma. Helena brings extensive experience in business development, partnerships and commercialization, while Vaidrius strengthens our medical capabilities ahead of the many launches and regulatory activities that are now underway. Together, they give us further strength in the next phase of Moberg Pharma’s development”, says Anna Ljung, CEO of Moberg Pharma AB.

Helena Jansson

Helena Jansson has more than 30 years of experience from leading positions in business management, business development and commercialization within life sciences. Helena has led global marketing, sales, and commercial operations which will add extensive cross-functional leadership experience and a proven track record in creating long-term partnerships and delivering growth to the company. Most recently, Helena held the position as Managing Director at Palette Life Sciences AB and has previously been responsible for the commercial portfolios of BioPhausia AB and Medivir AB.

Vaidrius Navikas

Vaidrius Navikas, MD, PhD, MBA, has more than 30 years of global experience in pharmaceutical development and commercialization. Prior to joining Moberg Pharma, he held positions at several pharmaceutical companies and academic institutions, most recently as Head of Global Medical Affairs at H. Lundbeck A/S. Vaidrius has extensive experience in clinical development, medical affairs, regulatory strategy, and scientific engagement.